CASI Pharmaceuticals Faces Nasdaq Delisting
Ticker: CASIF · Form: 6-K · Filed: Mar 13, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, appeal, nasdaq
Related Tickers: CASI
TL;DR
CASI stock is getting kicked off Nasdaq for being too cheap, but they're fighting it.
AI Summary
CASI Pharmaceuticals, Inc. received a notice on March 13, 2024, indicating that its common stock would be delisted from the Nasdaq Capital Market due to its failure to meet the minimum bid price requirement. The company plans to appeal this determination.
Why It Matters
This delisting could significantly impact the liquidity and trading of CASI's stock, potentially affecting investor confidence and access to capital.
Risk Assessment
Risk Level: high — The delisting from a major exchange like Nasdaq poses a significant risk to the company's liquidity, investor confidence, and future financing capabilities.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where stock is listed
FAQ
What was the primary reason for CASI Pharmaceuticals receiving a delisting notice?
CASI Pharmaceuticals received the notice because its common stock failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
When did CASI Pharmaceuticals receive the delisting notice?
The company received the notice on March 13, 2024.
What is CASI Pharmaceuticals' intended course of action regarding the delisting notice?
CASI Pharmaceuticals intends to appeal the determination by the Nasdaq staff.
What is the filing type and date for this report?
This is a Form 6-K filed on March 13, 2024.
What is the principal executive office address of CASI Pharmaceuticals?
The principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 14.5 · Accepted 2024-03-13 16:07:23
Filing Documents
- tmb-20240313x6k.htm (6-K) — 16KB
- 0001962738-24-000009.txt ( ) — 17KB
Forward-Looking Statements
Forward-Looking Statements This 6-K contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei (Larry) Zhang Name: Wei (Larry) Zhang Title: President Date: March 13, 2024